Mutant BRAF also downregulates the expression of melanoma differentiation antigens (MDA) and class I major histocompatibility complex (MHC-I) molecules on tumor cells, preventing their recognition by CD8+ T cells [13,14]. Here, CD8A is linked to melanoma.